Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2006-07-18
2006-07-18
Monshipouri, Maryam (Department: 1653)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C435S069100, C514S012200
Reexamination Certificate
active
07078485
ABSTRACT:
The invention relates to endostatin protein, in particular, to N-terminal modified recombinant human endostatin (rhEndostatin) proteins which have an additional metal chelating peptide sequence at the N-terminal, the preparation thereof, and methods of modifying the rhEndostatin to improve its stability in vivo and in vitro, and its biological activity. The invention further related to the resulting N-terminal modified rhEndostatin protein, a pharmaceutical composition containing the same, and use of said modified rhEndostatin or its pharmaceutical composition in treating the angiogenesis-related diseases, especially angiogenesis-dependent tumors.
REFERENCES:
patent: 6551840 (2003-04-01), Ono et al.
patent: 2004/0229338 (2004-11-01), King
patent: 00107569.1 (2001-12-01), None
patent: 00/48622 (2000-08-01), None
B. Kim Lee Sim et al., Zinc ligand-disrupted recombinant human Endostatin: Potent inhibition of tumor growth, safety and pharmokinetic profile, Angiogenesis, 1999, 41-51, Netherlands.
Noriko Yamaguchi et al., Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth indeoendently of zinc binding, The EMBO Journal, 1999, 18(16):4414-4423.
Michael S. O'Reilly et al., Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth, Cell, Jan. 24, 1997, 88:277-285.
Erhard Hohenester et al., Crystal Structure of the angiogenesis inhibitor endostatin at 1.5 Å resolution, The EMBO Journal, 1998, 17(6):1656-1664.
Yuan-Hua Ding et al., Zinc dependent dimers observed in crystals of human endostatin, Proc. Natl. Acad, Sci. USA, Sep. 1998, 95:10443-10448.
Thomas Boehm et al., Zinc-Binding of Endostatin id Essential for Its Antiangiogenic Activity, Biochemical and Biophysical Research Communications, 1998, 252:190-194.
Mohanraj Dhanabal et al., Cloning, Expression andin VitroActivity of Human Endostatin, Biochemical and Biophysical Research Communications, 1999, 258: 345-352.
Mohanraj Dhanabal et al., Endostatin: Yeast Production, Mutants, and Antitumor Effect in Renal Cell Carcinoma, Cancer Research, 1999, 59: 189-197.
Erhard Hohenester et al., Crystal structure of the angiogenesis inhibitor endostatin at 1.5 Å resolution, The EMBO Journal, 1998, 17(6): 1656-1664.
Judah Folkman, Clinical Applications of Research on Angiogenesis, Seminars in Medicine of the Beth Israel Hospital., Boston, 1995, 333(26): 1757-1763.
Judah Folkman and Yuen Shing, Angiogenesis, The Journal of Biological Chemistry, 1992, 267(16): 10931-10934.
Thomas Boehm et al, Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance, Letters to Nature, 1997, 390: 404-407.
Luo Yongzhang
Zhang Zhuobing
Zhou Bing
Monshipouri Maryam
Saliwanchik Lloyd & Saliwanchik
Yantai Medgenn Ltd.
LandOfFree
N-terminal modified recombinant human endostatin and its... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-terminal modified recombinant human endostatin and its..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-terminal modified recombinant human endostatin and its... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3603937